Co-Diagnostics, Inc. (CODX) · Nov 20, 2026 · New debt

Co-Diagnostics debt financing adds $1M but raises dilution risk

$1M secured loan — $960,000 net proceeds; $1.35M repayment obligation

Co-Diagnostics’ new debt financing brings in $960,000 net, but steep repayment terms, dilution risk and a reverse-split deadline deepen the funding pressure.

Co-Diagnostics is still a cash-burning molecular-diagnostics company trying to fund development of its Co-Dx PCR platform while commercial revenue remains very small. At September 30, 2026, it had only $0.7 million of cash, used $20.7 million in operating cash during the first nine months, and disclosed substantial doubt about its ability to continue as a going concern.

The financing buys near-term liquidity, but this was survival funding rather than growth funding. The additional tranche provides $1.0 million gross and $960,000 net for general working capital, which is meaningful against the company’s $0.7 million quarter-end cash balance. The direction was already known because the October loan agreement disclosed that CODX could draw the additional $1.0 million; the new information is that it drew the money early, after waiving several funding conditions.

Nov. 18, 2026Key comparison
Gross funding (Loan terms)$1.00M$0.7M cash at Sept. 30, 2026
Net cash proceeds (Loan terms)$0.96M$40,000 origination fee
Note principal (Loan terms)$1.35M$1.00M funded
Weekly installments (Loan terms)$45,00030 payments
Final maturity (Loan terms)June 16, 2027—
Default interest (Default provisions)19%Compounded daily

The price of that liquidity is unusually heavy and potentially dilutive. CODX must repay $1.35 million on $1.0 million funded, a 1.35x factor before other costs, through 30 weekly payments beginning November 25. The note is senior secured against substantially all company assets, can convert into stock at a discount to recent trading prices, and carries punitive default provisions including a 120% balance step-up and 19% daily-compounded default interest. 〔0〕 〔1〕

The funding is also tied to a near-term reverse-split deadline, underscoring the company’s financing and listing pressure. CODX waived the requirement that the reverse split already be effective before funding, but now must complete it by November 24, 2026 or face an event of default. 〔2〕

Bottom line: This keeps CODX funded in the immediate term, but it does not improve the underlying business economics. The early draw is useful, yet the expensive secured structure, conversion risk and reverse-split condition make the financing a modestly negative update to an already fragile liquidity story.

What to watch next

Reverse split effective by November 24, 2026

Original filing on SEC EDGAR

More Co-Diagnostics, Inc. news

Co-Diagnostics debt financing adds $1M but raises dilution risk | CODX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.